Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;94(7):2986-3005.
doi: 10.1002/jmv.27717. Epub 2022 Apr 5.

SARS-CoV-2 variants and vulnerability at the global level

Affiliations
Review

SARS-CoV-2 variants and vulnerability at the global level

Vivek P Chavda et al. J Med Virol. 2022 Jul.

Abstract

Numerous variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic have evolved. Viral variants may evolve with harmful susceptibility to the immunity established with the existing COVID-19 vaccination. These variants are more transmissible, induce relatively extreme illness, have evasive immunological features, decrease neutralization using antibodies from vaccinated persons, and are more susceptible to re-infection. The Centers for Disease Control and Prevention (CDC) has categorized SARS-CoV-2 mutations as variants of interest (VOI), variants of concern (VOC), and variants of high consequence (VOHC). At the moment, four VOC and many variants of interest have been defined and require constant observation. This review article summarizes various variants of SARS-CoV-2 surfaced with special emphasis on VOCs that are spreading across the world, as well as several viral mutational impacts and how these modifications alter the properties of the virus.

Keywords: Delta plus variant; Delta variant; Omicron variant; SARS-CoV-2; mutation; vaccination; viral variant.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Variants of SARS‐CoV‐2 and their clade. (SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2).
Figure 2
Figure 2
Mutations of SARS‐CoV‐2 VOCs, their clinical implications, and potential therapeutic targets (adopted under Creative Commons Attribution 4.0 International License from Khateeb and Zhang 17 ). SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; VOC, variants of concern.
Figure 3
Figure 3
The consequences of Delta variant and spike protein mutation.

References

    1. Chavda VP, Apostolopoulos V. Omicron variant (B.1.1.529) of SARS‐CoV‐2: threat for the elderly? Maturitas. 2022;158:78‐81. 10.1016/j.maturitas.2022.01.011 - DOI - PMC - PubMed
    1. Basu D, Chavda VP, Mehta AA. Therapeutics for COVID‐19 and post COVID‐19 complications: an update. Curr Res Pharmacol Drug Discov. 2022;3:100086. 10.1016/j.crphar.2022.100086 - DOI - PMC - PubMed
    1. Bian L, Gao F, Zhang J, et al. Effects of SARS‐CoV‐2 variants on vaccine efficacy and response strategies. Expert Rev Vaccines. 2021;20(4):365‐373. 10.1080/14760584.2021.1903879 - DOI - PMC - PubMed
    1. Kames J, Holcomb DD, Kimchi O, et al. Sequence analysis of SARS‐CoV‐2 genome reveals features important for vaccine design. Sci Rep. 2020;10(1):15643. 10.1038/s41598-020-72533-2 - DOI - PMC - PubMed
    1. Sanjuán R, Domingo‐Calap P. Mechanisms of viral mutation. Cell Mol Life Sci. 2016;73(23):4433‐4448. 10.1007/s00018-016-2299-6 - DOI - PMC - PubMed

Substances

Supplementary concepts